Reactor Ciudad Vieja: from abandoned properties to urban common goods: Collaborative Urbanism Laboratory in the historic center of Montevideo

In this article the research group Reactor Historic Centre Urban Laboratory (FADU- UDELAR), analyzes the planning process taken ahead in the last two years with the Urban Development Department of Montevideo’s city hall, around the renewal of empty buildings. The process demonstrated the sustainability of interventions based on associated management of the renewal processes with civil society groups and local government. The projects were organized around four main issues; Transformative Economies; Arts, culture and care; Ecology and Collaborative Housing. The results reached until now show how appropriate could be a pilot public programme as a way of renewing the urban strategies of intervention in central areas, as well as participatory models in urban management and the growing urban commons role into Right to the city challenges.En esta ponencia el grupo de investigación Laboratorio urbano Reactor Ciudad Vieja[1] (FADU-UdelaR), analiza el trabajo realizado durante dos años en convenio con el departamento de Desarrollo Urbano de la Intendencia de Montevideo, en torno a la expropiación y recuperación de inmuebles vacantes vacíos y degradados. El proceso demostró la factibilidad de las intervenciones de recuperación de inmuebles abandonados a partir de la gestión asociada de varios colectivos y la administración departamental, con un programa de usos cívicos basado en cuatro ejes: Economías Transformadoras; Arte, Cultura y Cuidados; Ecología; Formas Colaborativas de Habitar.  Los resultados alcanzados dan cuenta de la pertinencia del desarrollo del programa piloto público como forma de renovar el repertorio de intervención urbana en áreas consolidadas, la discusión del papel de la participación en la gestión urbanística y la creciente estrategia de consolidar los bienes comunes urbanos para asegurar el Derecho a la Ciudad.   [1] https://www.reactoruy.comPeer Reviewe

Panel 4: Pueblos indígenas: temas prioritarios. Aportes/obstáculos desde la Antropología

El panel “Pueblos indígenas: temas prioritarios. Aportes/obstáculos desde la Antropología”, coordinado y editado por Stella García y Lucia Mazzitelli, tuvo como objetivo abrir un espacio de intercambio y debate para que referentes de pueblos indígenas de Argentina definan temas que consideren prioritarios en el marco de sus luchas, demandas y reivindicaciones actuales. Propuso también, revisar la tarea históricamente realizada por la Antropología en este campo y delinear posibles aportes a futuro, en miras de construir una disciplina comprometida con las problemáticas de los Pueblos Indígenas, y buscando abordarlas como un desafío necesario y urgente. Se presentan aquí las exposiciones realizadas por lxs panelistas: Ignacio Rossi -referente del pueblo Qom, de la localidad de Resistencia (Chaco)-; María Luisa Pereyra -referenta del pueblo Tonokoté de Santiago del Estero-; Isabel Araujo Pincén -miembro de la comunidad Indígena Cacique Pincén Mapuche-Tehuelche de Trenque Lauquen (Buenos Aires)-; Néstor Jerez -Cacique del Pueblo Ocloya (Jujuy)-; Patricia Segundo -consejera de la mujer de la Comunidad Iwi Imemb’y del pueblo Ava Guaraní, de la localidad de La Plata (Buenos Aires).Panel 4: Pueblos indígenas: temas prioritarios. Aportes/obstáculos desde la Antropología.Universidad Nacional de La Plat

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial

Background The best treatment option for patients with type 2 diabetes in whom treatment with metformin alone fails to achieve adequate glycaemic control is debated. We aimed to compare the long-term effects of pioglitazone versus sulfonylureas, given in addition to metformin, on cardiovascular events in patients with type 2 diabetes. Methods TOSCA.IT was a multicentre, randomised, pragmatic clinical trial, in which patients aged 50\ue2\u80\u9375 years with type 2 diabetes inadequately controlled with metformin monotherapy (2\ue2\u80\u933 g per day) were recruited from 57 diabetes clinics in Italy. Patients were randomly assigned (1:1), by permuted blocks randomisation (block size 10), stratified by site and previous cardiovascular events, to add-on pioglitazone (15\ue2\u80\u9345 mg) or a sulfonylurea (5\ue2\u80\u9315 mg glibenclamide, 2\ue2\u80\u936 mg glimepiride, or 30\ue2\u80\u93120 mg gliclazide, in accordance with local practice). The trial was unblinded, but event adjudicators were unaware of treatment assignment. The primary outcome, assessed with a Cox proportional-hazards model, was a composite of first occurrence of all-cause death, non-fatal myocardial infarction, non-fatal stroke, or urgent coronary revascularisation, assessed in the modified intention-to-treat population (all randomly assigned participants with baseline data available and without any protocol violations in relation to inclusion or exclusion criteria). This study is registered with ClinicalTrials.gov, number NCT00700856. Findings Between Sept 18, 2008, and Jan 15, 2014, 3028 patients were randomly assigned and included in the analyses. 1535 were assigned to pioglitazone and 1493 to sulfonylureas (glibenclamide 24 [2%], glimepiride 723 [48%], gliclazide 745 [50%]). At baseline, 335 (11%) participants had a previous cardiovascular event. The study was stopped early on the basis of a futility analysis after a median follow-up of 57\uc2\ub73 months. The primary outcome occurred in 105 patients (1\uc2\ub75 per 100 person-years) who were given pioglitazone and 108 (1\uc2\ub75 per 100 person-years) who were given sulfonylureas (hazard ratio 0\uc2\ub796, 95% CI 0\uc2\ub774\ue2\u80\u931\uc2\ub726, p=0\uc2\ub779). Fewer patients had hypoglycaemias in the pioglitazone group than in the sulfonylureas group (148 [10%] vs 508 [34%], p<0\uc2\ub70001). Moderate weight gain (less than 2 kg, on average) occurred in both groups. Rates of heart failure, bladder cancer, and fractures were not significantly different between treatment groups. Interpretation In this long-term, pragmatic trial, incidence of cardiovascular events was similar with sulfonylureas (mostly glimepiride and gliclazide) and pioglitazone as add-on treatments to metformin. Both of these widely available and affordable treatments are suitable options with respect to efficacy and adverse events, although pioglitazone was associated with fewer hypoglycaemia events. Funding Italian Medicines Agency, Diabete Ricerca, and Italian Diabetes Society